臨床試験

A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation

NCT: NCT07073950 · RECRUITING

NCT識別子NCT07073950

ステータスRECRUITING

開始日2025-11-24

完了2027-05-31

SponsorAstraZeneca (INDUSTRY)

First posted2025-07-20

Last updated2026-09-18

概要

The purpose of the study is to evaluate the effect of BGF MDI compared with placebo MDI on cardiac and lung function when administered in participants diagnosed with COPD and hyperinflation.

公式ソース

ClinicalTrials.govで見る →

データはClinicalTrials.gov APIから取得しています。最新のステータスは公式記録をご確認ください。